Onyx Pharmaceuticals ($ONXX) CEO Tony Coles has held his cards about his company's sales process close to the vest. In keeping with this practice, the chief executive kept his comments about the process vague and brief during a second-quarter earnings call Thursday following reports that Amgen ($AMGN) alone was readying a $130-per-share deal to acquire his company. "The process is ongoing with multiple parties currently engaged in discussions," Coles said, as quoted by Bloomberg. The comment doesn't necessarily say that multiple bidders are still interested in Onyx, but one could interpret it that way. In which case Amgen might face some competition in its pursuit of South San Francisco-based Onyx. More